Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
Harvard Business School
Mallinckrodt
McKesson
Dow

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,271,025

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,271,025
Title: Modified factor VIII cDNA
Abstract:A modified Factor VIII cDNA is described comprising deletion of the B-domain and insertion of at least one truncated Factor IX intron 1 in the Factor VIII cDNA. The modified Factor VIII cDNA may be used for the production of a high yield of Factor VIII in vitro. The modified Factor VIII cDNA may be incorporated into a vector for gene therapy.
Inventor(s): Negrier; Claude (Irigny, FR), Plantier; Jean Luc (Grigny, FR)
Assignee: Aventis Behring GmbH (Marburg, DE)
Application Number:09/526,935
Patent Claims:1. A modified Factor VIII cDNA comprising a deletion of the B-domain and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA, wherein said cDNA encodes a polypeptide having Factor VIII activity.

2. A modified Factor VIII cDNA comprising a replacement of the B-domain with nucleotides encoding four arginines and insertion of the truncated Factor IX intron 1 (SEQ ID NO: 9) in one or more splice sites of the Factor VIII cDNA, wherein said cDNA encodes a polypeptide having Factor VIII activity.

3. The modified Factor VIII cDNA as claimed in claim 1, wherein at least one insertion site of the truncated Factor IX intron 1 is chosen from Factor VIII intron 1 splice site, Factor VIII intron 12 splice site, and Factor VIII intron 13 splice site.

4. The modified Factor VIII cDNA as claimed in claim 2, wherein at least one insertion site of the truncated Factor IX intron 1 is chosen from Factor VIII intron 1 splice site, Factor VIII intron 12 splice site, and Factor VIII intron 13 splice site.

5. A vector comprising the modified Factor VIII cDNA of claim 1.

6. A vector comprising the modified Factor VIII cDNA of claim 2.

Details for Patent 6,271,025

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2019-03-17
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2019-03-17
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
Mallinckrodt
Express Scripts
Baxter
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.